Oruka Therapeutics (NASDAQ:ORKA) Receives New Coverage from Analysts at TD Cowen

TD Cowen began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report published on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating on the stock.

ORKA has been the subject of several other research reports. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a report on Friday, September 13th. They set a buy rating and a $40.00 price target for the company. Wedbush assumed coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an outperform rating and a $40.00 price target for the company. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $41.25.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock opened at $25.38 on Monday. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.